Patents by Inventor Soongyu Choi
Soongyu Choi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240067646Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.Type: ApplicationFiled: July 26, 2023Publication date: February 29, 2024Inventors: Hongyan QI, Soongyu CHOI, Amal DAKKA, Gary Mitchell KARP, Jana NARASIMHAN, Nikolai NARYSHKIN, Anthony A. TURPOFF, Marla L. WEETALL, Ellen WELCH, Matthew G. WOLL, Tianle YANG, Nanjing ZHANG, Xiaoyan ZHANG, Xin ZHAO, Luke GREEN, Emmanuel PINARD, Hasane RATNI
-
Patent number: 11753407Abstract: Provided herein are compounds of Formula (I): and forms thereof, wherein w1, w2, w3, w4, w5, w6 and w7 are as defined herein, including compositions thereof and uses therewith for treating spinal muscular atrophy.Type: GrantFiled: October 5, 2020Date of Patent: September 12, 2023Assignees: PTC Therapeutics, Inc., F. Hoffmann-La Roche AGInventors: Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Yurpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
-
Publication number: 20210276999Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.Type: ApplicationFiled: October 5, 2020Publication date: September 9, 2021Inventors: Hongyan QI, Soongyu CHOI, Amal DAKKA, Gary Mitchell KARP, Jana NARASIMHAN, Nikolai NARYSHKIN, Anthony A. TURPOFF, Marla L. WEETALL, Ellen WELCH, Matthew G. WOLL, Tianle YANG, Nanjing ZHANG, Xiaoyan ZHANG, Xin ZHAO, Luke GREEN, Emmanuel PINARD, Hasane RATNI
-
Patent number: 10889574Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: August 30, 2019Date of Patent: January 12, 2021Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Patent number: 10851101Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.Type: GrantFiled: August 15, 2019Date of Patent: December 1, 2020Assignees: PTC Therapeutics, Inc., F. Hoffman-La Roche AGInventors: Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
-
Patent number: 10851175Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.Type: GrantFiled: September 23, 2016Date of Patent: December 1, 2020Assignees: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATIONInventors: Dong-Sik Kim, Eun Jung Song, Mijung Lee, Eun-Hee Lee, Miyoung Oh, Jae Chan Park, Kisu Kim, Sujeong Kim, Hyung-Kwon Lim, Kyuhyun Lee, Jongwha Won, Soongyu Choi, Young Seoub Park
-
Patent number: 10752697Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.Type: GrantFiled: October 27, 2016Date of Patent: August 25, 2020Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCHInventors: Jae Chan Park, Kisu Kim, Mijung Lee, Eun-Hee Lee, Dong-Sik Kim, Eun Jung Song, Sujeong Kim, Hyung-Kwon Lim, Kyuhyun Lee, Jongwha Won, Soongyu Choi, Young Seoub Park
-
Patent number: 10640496Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: GrantFiled: June 15, 2017Date of Patent: May 5, 2020Assignees: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon Yoon, Se-Hwan Park, Ji-sung Yoon, Soongyu Choi, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Kwang-Seop Song, Min Ju Kim, So Ok Park
-
Patent number: 10584115Abstract: Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.Type: GrantFiled: November 21, 2013Date of Patent: March 10, 2020Assignee: PTC THERAPEUTICS, INC.Inventors: Ramil Baiazitov, Soongyu Choi, Wu Du, Seongwoo Hwang, Chang-Sun Lee, Ronggang Liu, Young-Choon Moon, Steven D. Paget, Hongyu Ren, Nadiya Sydorenko, Richard Gerald Wilde
-
Publication number: 20190382390Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: ApplicationFiled: August 30, 2019Publication date: December 19, 2019Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
-
Publication number: 20190375750Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.Type: ApplicationFiled: August 15, 2019Publication date: December 12, 2019Inventors: Hongyan QI, Soongyu CHOI, Amal DAKKA, Gary Mitchell KARP, Jana NARASIMHAN, Nikolai NARYSHKIN, Anthony A. TURPOFF, Marla L. WEETALL, Ellen WELCH, Matthew G. WOLL, Tianle YANG, Nanjing ZHANG, Xiaoyan ZHANG, Xin ZHAO, Luke GREEN, Emmanuel PINARD, Hasane RATNI
-
Publication number: 20190169174Abstract: The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.Type: ApplicationFiled: June 15, 2017Publication date: June 6, 2019Applicants: DAEWOONG PHARMACEUTICAL CO., LTD., GREEN CROSS CORPORATIONInventors: Hee-kyoon YOON, Se-Hwan PARK, Ji-Sung YOON, Soongyu CHOI, Hee Jeong SEO, Eun-Jung PARK, Younggyu KONG, Kwang-Seop SONG, Min Ju KIM, So Ok PARK
-
Pyrazole derivatives as TNIK, IKK? and TBK1 inhibitor and pharmaceutical composition comprising same
Patent number: 10294207Abstract: Provided is pyrazole derivatives as a TNIK (Traf2- and NCK-interacting kinase), IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor; the pyrazole derivative according to the present invention effectively inhibits TNIK, IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 29, 2016Date of Patent: May 21, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kisoo Park, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, Ickhwan Son, Sang-ho Ma, Kwang-Seop Song, Min Ju Kim, So Ok Park, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong -
Patent number: 10239873Abstract: Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKK? (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKK? and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.Type: GrantFiled: March 24, 2016Date of Patent: March 26, 2019Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang-Seop Song, Hee Jeong Seo, Sang-ho Ma, Eun-Jung Park, Younggyu Kong, So Ok Park, Kisoo Park, Ickhwan Son, Min Ju Kim, Man-Young Cha, Mi-Soon Kim, Sang Mi Kang, Dong Hyuk Jang, Jangwon Hong
-
Publication number: 20180346592Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.Type: ApplicationFiled: October 27, 2016Publication date: December 6, 2018Inventors: Jae Chan PARK, Kisu KIM, Mijung LEE, Eun-Hee LEE, Dong-Sik KIM, Eun Jung SONG, Sujeong KIM, Hyung-Kwon LIM, Kyuhyun LEE, Jongwha WON, Soongyu CHOI, Young Seoub PARK
-
Publication number: 20180346588Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.Type: ApplicationFiled: September 23, 2016Publication date: December 6, 2018Applicants: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH, GREEN CROSS CORPORATIONInventors: Dong-Sik KIM, Eun Jung SONG, Mijung LEE, Eun-Hee LEE, Miyoung OH, Jae Chan PARK, Kisu KIM, Sujeong KIM, Hyung-Kwon LIM, Kyuhyun LEE, Jongwha WON, Soongyu CHOI, Young Seoub PARK
-
Patent number: 9988372Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.Type: GrantFiled: July 18, 2014Date of Patent: June 5, 2018Assignees: GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES, INC.Inventors: Soongyu Choi, Jungsub Choi, So-Hyun Yoon, Yoo Hoon Kim, Jae Yeon Kim, Suk Ho Lee, Young Lag Cho, Ho Young Song, Dae Yon Lee, Sung Yoon Baek, Sang Eun Chae, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Publication number: 20180105526Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.Type: ApplicationFiled: December 20, 2017Publication date: April 19, 2018Inventors: Hongyan QI, Soongyu CHOI, Amal DAKKA, Gary Mitchell KARP, Jana NARASIMHAN, Nikolai NARYSHKIN, Anthony A. TURPOFF, Marla L. WEETALL, Ellen WELCH, Matthew G. WOLL, Tianle YANG, Nanjing ZHANG, Xiaoyan ZHANG, Xin ZHAO, Luke GREEN, Emmanuel PINARD, Hasane RATNI
-
Patent number: 9879007Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.Type: GrantFiled: August 26, 2016Date of Patent: January 30, 2018Assignees: PTC Therapeutics, Inc., F. Hoffmann-La Roche AGInventors: Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
-
Patent number: RE47689Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.Type: GrantFiled: September 5, 2017Date of Patent: November 5, 2019Assignees: PTC Therapeutics, Inc., F. Hoffmann-La RocheInventors: Matthew G. Woll, Guangming Chen, Soongyu Choi, Amal Dakka, Song Huang, Gary Mitchell Karp, Chang-Sun Lee, Chunshi Li, Jana Narasimhan, Nikolai Naryshkin, Sergey Paushkin, Hongyan Qi, Anthony A. Turpoff, Marla L. Weetall, Ellen Welch, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Emmanuel Pinard, Hasane Ratni